Zentalis to Present Azenosertib-Paclitaxel Phase 1b Data for Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals announced ASCO acceptance for Abstract 5529 on June 1, 2026, presenting Part 1 Phase 1b MUIR trial data combining azenosertib with paclitaxel in platinum-resistant ovarian cancer patients. The study evaluates safety, tolerability and preliminary efficacy, including objective response rate and progression-free survival, supporting broader development strategy.
1. ASCO Abstract Acceptance and Presentation Details
Zentalis Pharmaceuticals has secured acceptance of Abstract 5529 for presentation at the 2026 ASCO Annual Meeting on June 1, 2026 in Chicago. The poster session (Gynecologic Cancer, Board 195) will showcase data from Part 1 of the MUIR trial evaluating azenosertib combined with paclitaxel in platinum-resistant ovarian cancer.
2. Phase 1b MUIR Trial Part 1 Results
Part 1 of MUIR is an open-label Phase 1b study enrolling platinum-resistant ovarian cancer patients to assess safety, tolerability and preliminary activity of azenosertib plus paclitaxel. Key secondary endpoints include objective response rate, duration of response and progression-free survival per RECIST v1.1 criteria.
3. Broader Development and Pipeline Strategy
Zentalis is advancing azenosertib as a first-in-class WEE1 inhibitor with a focus on Cyclin E1-positive platinum-resistant ovarian cancer. The company is running monotherapy registration trials (DENALI, ASPENOVA) and pursuing companion diagnostic validation, backed by FDA Fast Track designation, to accelerate its biomarker-driven pipeline.